EP2259800
Use of 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine for the treatment of non small cell lung carcinoma with acquired resistance to epidermal growth factor receptor (EGFR) modulators.
Status:
EP einkaleyfi: Þýðing ekki lögð innEP appl. date:
4.3.2009EP published:
7.5.2014EP application number:
09716778.7
EPO information:
European Patent Register
Max expiry date:
3.3.2029
Title:
Use of 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine for the treatment of non small cell lung carcinoma with acquired resistance to epidermal growth factor receptor (EGFR) modulators.
Timeline
Today
4.3.2009EP application
7.5.2014EP Publication
Owner
Name:
Novartis AGAddress:
Lichtstrasse 35, 4056, Basel, CH
Inventor
Name:
GARCIA-ECHEVERRIA, CarlosAddress:
Basel, CH
Name:
MAIRA, Sauveur-MichelAddress:
Habsheim, FR
Priority
Number:
08152326Date:
5.3.2008Country:
EP
Classification
Categories:
A61K 45/06, A61P 35/00, A61K 31/5377